Management & Regulatory

Can Donanemab Transform Early Alzheimer’s Treatment in Europe?
Management & Regulatory Can Donanemab Transform Early Alzheimer’s Treatment in Europe?

What if a single monthly infusion could halt the heartbreaking decline of memory and independence for millions of Europeans with early Alzheimer’s disease, bringing hope to families across the continent? This question, once a distant dream, now edges closer to reality with donanemab, a pioneering

How Does Sarclisa Redefine Multiple Myeloma Treatment?
Management & Regulatory How Does Sarclisa Redefine Multiple Myeloma Treatment?

In the complex world of oncology, multiple myeloma (MM) stands as a formidable challenge, affecting thousands across Europe with its intricate disease mechanisms and diverse patient needs. As the second most common blood cancer after non-Hodgkin lymphoma, MM impacts around 46,000 new individuals

EMA Endorses Moderna's Updated Vaccine for 2025-2026 Season
Management & Regulatory EMA Endorses Moderna's Updated Vaccine for 2025-2026 Season

The European Medicines Agency (EMA) has recommended the approval of Moderna's LP.8.1-adapted COVID-19 vaccine to address the challenges posed by the SARS-CoV-2 variant LP.8.1. Following the guidance of EMA's Emergency Task Force, the formulation of Spikevax has been tailored to combat the current

FDA Grants Priority Review to Imfinzi for Early Gastric Cancer
Management & Regulatory FDA Grants Priority Review to Imfinzi for Early Gastric Cancer

In the ever-evolving landscape of cancer treatment, AstraZeneca’s Imfinzi represents a significant step forward in managing early-stage gastric cancer. Ivan Kairatov, a biopharmaceutical expert with a wealth of knowledge in biotechnology and innovation, shares insights into how this immunotherapy

Can Elahere Transform Ovarian Cancer Treatment in the UK?
Management & Regulatory Can Elahere Transform Ovarian Cancer Treatment in the UK?

Imagine a world where ovarian cancer treatment defies conventional boundaries, offering renewed optimism to thousands of patients facing limited options. This vision takes form with Elahere, an emerging therapeutic choice now approved in the UK for those resistant to platinum-based

Will Blenrep Transform Multiple Myeloma Treatment in Europe?
Management & Regulatory Will Blenrep Transform Multiple Myeloma Treatment in Europe?

With multiple myeloma cases surpassing 50,000 annually across Europe, the quest for a more effective treatment has never been more urgent. Despite its classification as a rare cancer, its profound impact on affected individuals and healthcare systems is undeniable. Imagine a treatment that could

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later